Literature DB >> 23747790

Effects of nesiritide and predictors of urine output in acute decompensated heart failure: results from ASCEND-HF (acute study of clinical effectiveness of nesiritide and decompensated heart failure).

Stephen S Gottlieb1, Amanda Stebbins, Adriaan A Voors, Vic Hasselblad, Justin A Ezekowitz, Robert M Califf, Christopher M O'Connor, Randall C Starling, Adrian F Hernandez.   

Abstract

OBJECTIVES: This study sought to determine if nesiritide increases diuresis in congestive heart failure patients.
BACKGROUND: In the ASCEND-HF (Acute Study of Clinical Effectiveness of Nesiritide and Decompensated Heart Failure), 7,141 patients hospitalized with acute decompensated heart failure (ADHF) were randomized to receive nesiritide or placebo for 24 to 168 h, in addition to standard care. There were minimal effects of nesiritide on survival, future hospitalizations, and symptoms. However, whether or not nesiritide increases diuresis in ADHF patients is unknown.
METHODS: Urine output was measured in 5,864 subjects; of these, 5,320 received loop diuretics and had dose data recorded. Loop diuretics other than furosemide were converted to furosemide equivalent doses. A total of 4,881 patients had complete data. We used logistic regression models to identify the impact of nesiritide on urine output and the factors associated with high urine output.
RESULTS: Median (25th, 75th percentiles) 24-h urine output was 2,280 (1,550, 3,280) ml with nesiritide and 2,200 (1,550, 3,200) ml with placebo (p = NS). Loop diuretic dose (furosemide equivalent) was 80 (40, 140) mg with both nesiritide and placebo. Diuretic dose was a strong predictor of urine output. Other independent predictors included: male sex, greater body mass index, higher diastolic blood pressure, elevated jugular venous pressure, recent weight gain, and lower blood urea nitrogen. The addition of nesiritide did not change urine output. None of the interaction terms between nesiritide and predictors affected the urine output prediction.
CONCLUSIONS: Nesiritide did not increase urine output in patients with ADHF. Higher diuretic dose was a strong predictor of higher urine output, but neurohormonal activation (as evidenced by blood urea nitrogen concentration) and lower blood pressure limited diuresis.
Copyright © 2013 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ADHF; B-type natriuretic peptide; BMI; BNP; BUN; acute decompensated heart failure; blood urea nitrogen; body mass index; diuresis; eGFR; estimated glomerular filtration rate; nesiritide

Mesh:

Substances:

Year:  2013        PMID: 23747790     DOI: 10.1016/j.jacc.2013.04.073

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  26 in total

Review 1.  New insights into combinational drug therapy to manage congestion in heart failure.

Authors:  Frederik Hendrik Verbrugge; Lars Grieten; Wilfried Mullens
Journal:  Curr Heart Fail Rep       Date:  2014-03

Review 2.  Diuretic response in acute heart failure-pathophysiology, evaluation, and therapy.

Authors:  Jozine M ter Maaten; Mattia A E Valente; Kevin Damman; Hans L Hillege; Gerjan Navis; Adriaan A Voors
Journal:  Nat Rev Cardiol       Date:  2015-01-06       Impact factor: 32.419

Review 3.  Current Approach to Decongestive Therapy in Acute Heart Failure.

Authors:  Pieter Martens; Petra Nijst; Wilfried Mullens
Journal:  Curr Heart Fail Rep       Date:  2015-12

Review 4.  Decongestion in acute heart failure.

Authors:  Robert J Mentz; Keld Kjeldsen; Gian Paolo Rossi; Adriaan A Voors; John G F Cleland; Stefan D Anker; Mihai Gheorghiade; Mona Fiuzat; Patrick Rossignol; Faiez Zannad; Bertram Pitt; Christopher O'Connor; G Michael Felker
Journal:  Eur J Heart Fail       Date:  2014-03-05       Impact factor: 15.534

Review 5.  Loop diuretic resistance complicating acute heart failure.

Authors:  Zachary L Cox; Jeffrey M Testani
Journal:  Heart Fail Rev       Date:  2020-01       Impact factor: 4.214

Review 6.  Current and Potential Therapeutic Strategies for Hemodynamic Cardiorenal Syndrome.

Authors:  Yoshitsugu Obi; Taehee Kim; Csaba P Kovesdy; Alpesh N Amin; Kamyar Kalantar-Zadeh
Journal:  Cardiorenal Med       Date:  2015-11-06       Impact factor: 2.041

7.  Body Weight Change During and After Hospitalization for Acute Heart Failure: Patient Characteristics, Markers of Congestion, and Outcomes: Findings From the ASCEND-HF Trial.

Authors:  Andrew P Ambrosy; Lukasz P Cerbin; Paul W Armstrong; Javed Butler; Adrian Coles; Adam D DeVore; Mark E Dunlap; Justin A Ezekowitz; G Michael Felker; Marat Fudim; Stephen J Greene; Adrian F Hernandez; Christopher M O'Connor; Philip Schulte; Randall C Starling; John R Teerlink; Adriaan A Voors; Robert J Mentz
Journal:  JACC Heart Fail       Date:  2017-01       Impact factor: 12.035

8.  Targeting the kidney in acute heart failure: can old drugs provide new benefit? Renal Optimization Strategies Evaluation in Acute Heart Failure (ROSE AHF) trial.

Authors:  Horng H Chen; Omar F AbouEzzeddine; Kevin J Anstrom; Michael M Givertz; Bradley A Bart; G Michael Felker; Adrian F Hernandez; Kerry L Lee; Eugene Braunwald; Margaret M Redfield
Journal:  Circ Heart Fail       Date:  2013-09-01       Impact factor: 8.790

9.  Effects of recombinant human brain natriuretic peptide on renal function in patients with acute heart failure following myocardial infarction.

Authors:  Yanbo Wang; Xinshun Gu; Weize Fan; Yanming Fan; Wei Li; Xianghua Fu
Journal:  Am J Transl Res       Date:  2016-01-15       Impact factor: 4.060

Review 10.  Incorporating common biomarkers into the clinical management of heart failure.

Authors:  Meghana Halkar; W H Wilson Tang
Journal:  Curr Heart Fail Rep       Date:  2013-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.